Status: Recruiting
Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
This is a Phase II randomized, double-blind, placebo-controlled trial of sildenafil in men and women with Scleroderma with mildly elevated pulmonary pressures (SSc-MEP) to determine whether sildenafil may be an effective treatment for SSc-MEP.
Participants needed: 30
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Johns Hopkins UniversityUpdated: Oct 15, 2025Locations: 2
Eligibility criteria
Previous documentation of mean pulmonary artery pressure between 21 and 24 mm Hg... [+5]
World Health Organization (WHO) Class IV functional status. [+10]